Bayer: Finerenone drug lowers cardiovascular events

(CercleFinance.com) - Bayer's Finerenone significantly cut the risk of cardiovascular events in patients with chronic kidney disease and type 2 diabetes in a late-stage clinical trial, data showed on Tuesday.


Results from a Phase III study indicate that compared to placebo, Finerenone reduced the composite cardiovascular endpoint consistently in patients with chronic kidney disease and type 2 diabetes (T2D), with or without history of cardiovascular disease, Bayer said.

The presentation, made at at the American Heart Association (AHA) scientific sessions, underscores the drug's potential in cardiovascular prevention in these patients, the company said.

"Patients with chronic kidney disease and type 2 diabetes are not only at high risk of progression to kidney failure, they are also exposed to a higher risk of cardiovascular events - and face substantial cardiovascular morbidity and mortality," said Gerasimos Filippatos, a professor of cardiology at the National and Kapodistrian University of Athens, Greece, and an investigator of the trial.

Finerenone is an investigational, non-steroidal drug that blocks the harmful effects of mineralocorticoid receptor overactivation, a driver of kidney and cardiovascular damage through inflammatory and fibrotic processes.

Copyright (c) 2020 CercleFinance.com. All rights reserved.